The Pharma Data

DECEMBER 17, 2020

Currently, healthcare personnel and long-term care facility residents participating in their trial are the only ones who can opt to receive the vaccine.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

DECEMBER 10, 2020

First in line are health care personnel and residents and staff of long-term care facilities, according to earlier recommendations released by the CDC panel. Doctors say this reflects India’s younger and leaner population.

Vaccine 52

Vaccine FDA Long-Term Care Facilities Hospitals 52

The Pharma Data

DECEMBER 4, 2020

The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. An FDA advisory panel is set to meet on Dec.

Vaccine 52

Vaccine Long-Term Care Facilities Nurses Hospitals 52

The Pharma Data

DECEMBER 3, 2020

The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. An FDA advisory panel is set to meet on Dec.

Hospitals 52

Hospitals Vaccine Long-Term Care Facilities Nurses 52

The Pharma Data

DECEMBER 2, 2020

The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities.

Vaccine 40

Vaccine Long-Term Care Facilities Hospitals Nurses 40

The Pharma Data

NOVEMBER 9, 2020

“This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients – adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic,” said David A. Ricks, Lilly’s chairman and CEO.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

JANUARY 26, 2021

Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration. It remains under review by the FDA. A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52